CTIS2022-502948-13-00进行中（未招募）1 期
A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab for locally advanced or Metastatic Hepatocellular Carcinoma patients who have progressed after an approved immune checkpoint inhibitor containing regimen in First-Line HCC - M24-147
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Child-Pugh A ECOG PS 0-1 Received an immune checkpoint inhibitor in 1L HCC treatment regimen.No symptomatic, untreated, or actively progressing CNS metastases. Adequate hematologic and end-organ function Tissue biopsy at screening
排除标准
- •No history of malignancy other than HCC within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate > 90%),, No major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study, No prior allogeneic stem cell or solid organ transplantation, Resolution of any acute clinically significant treatment-related toxicity from prior therapy to Grade = 1 prior to study entry, except for alopecia., Negative HIV test at screening due to potential safety concerns on those immune compromised patients.
研究者
相似试验
招募中
2 期
A randomized phase II study investigating an optimal dosing regimen of TS-1 plus CDDP plus Trastuzumab combination therapy for HER2-positive unresectable and/or recurrent gastric cancernresectable and/or recurrent gastric cancerJPRN-UMIN000008254Juntendo University School of Medicine Department of Gastroenterology40
已完成
不适用
A randomized phase II trial to investigate optimal duration (4 month versus 6 month) of preoperative endocrine therapybreast cancerJPRN-UMIN000005668ational Cancer Center Hospital50
已完成
2 期
A randomized phase II study for the evaluation of T cell depleted non-myeloablative allogeneic stem cell transplantation followed by early consolidation with lenalidomide or lenalidomide combined with bortezomib and subsequent DLI for patients with multiple myeloma in progression or relapse following first line therapyKahlers disease10035227Multiple MyelomaNL-OMON36688HOVO110
招募中
1 期
ocally Advanced or Metastatic Hepatocellular Carcinoma: Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab in Subjects Who Have Not Previously Received Systemic Treatment – LIVIGNO-2Metastatic Hepatocellular Carcinoma (HCC)CTIS2023-504600-28-00AbbVie Deutschland GmbH & Co. KG80
进行中（未招募）
1 期
A study to optimize immunotherapy in head and neck cancerrecurrent or metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN) progressing after prior platinum-based therapy (radiochemo-therapy or systemic chemotherapy)MedDRA version: 20.0Level: PTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10071540Term: Head and neck cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003349-14-DEAIO-Studien-gGmbH280